biotechandmoney

Annual awards

Supported by:

CLINIGEN Group plc

CMS Law.Tax

EQS GROUP

J A KEMP

biotechandmoney
bringing deals to life

The 2017 Awards

Each year the **Biotech and Money Assembly and Awards** recognises the UK and Ireland's greatest funding, investment and deal making successes in the sector through 12 hotly contested Awards.

We believe that judging the industry's financial success stories should be a peer review process within that industry, meaning the Awards is a truly unique, real-time, peer-voted ceremony dedicated exclusively to UK and Irish life science investment and partnering achievements.

We're delighted that London's prestigious Merchant Taylors Hall will play host to 250 C-Level life science Executives and their investor and advisor network, as the 90+ finalists vie to take home an Award and the prestige associated with winning. We'd also like to thank our supporting partners for their hosting of a number of the Awards.

This year's finalists were whittled down from hundreds of nominations by our 70+ strong judging faculty. What is presented in this document are the finalists from the several rounds of voting.

Specific criteria was placed around each category and the qualification period ranged from 1st June 2016 - 1st June 2017. Information used to support tonight's live vote was collated from relevant company press releases within this time frame.

There are very few occasions in a year when life science Executives have the opportunity to recognise, influence and celebrate the achievements of their peers. The 2017 Biotech and Money Assembly and Awards is one of those occasions.

We wish you an enjoyable, and for those nominated, a successful evening.

The Biotech and Money Awards Team

Order of Evening

6.00pm Champagne Reception in the Courtyard Gardens with music from Black Tie Jazz
7.30pm Call for dinner
7.40pm Guests seated and welcome remarks
7.45pm 3-Course Gala Dinner with wine
9.15pm Guest speaker: Dr David Reynolds, Chief Scientific Officer, Alzheimer's Research UK
9.30pm Charity raffle and donations
9.45pm Awards ceremony and live voting
10.45pm Cash bar
11.30pm Close

2017 Charity

Alzheimer's Research UK

The Power to Defeat Dementia

Alzheimer's Research UK firmly believes in the power of research to create a world free from the fear, harm and heartbreak of dementia. ARUK's approach to research spans three areas that will nurture discovery and ideas as well as translating findings from this research into benefits for people with dementia. Alzheimer's Research UK is dedicated to funding the best quality science and the most ambitious ideas that will take us closer to defeating dementia.

Without effective treatments, one in three children born today will die with dementia. Today, there are no dementia survivors but research can change this.

Alzheimer's Research UK is the world's leading dementia research charity dedicated to causes, diagnosis, prevention, treatment and cure. Backed by our passionate scientists and supporters, ARUK are challenging the way people think about dementia, uniting the big thinkers in the field and funding the innovative science that will deliver a cure.

ARUK's mission is to bring about the first life-changing dementia treatment by 2025.

With their support, they will focus their energies in four key areas of action to make this mission a reality.

- Understand the diseases that cause dementia.
- Diagnose people earlier and more accurately.
- Reduce risk, backed by the latest evidence.
- Treat dementia effectively.

Through these important strands of work, ARUK are bringing about breakthroughs that will change lives.

Biotech and Money is delighted to have chosen Alzheimer's Research UK as this year's Awards Charity.

Donations will be raised on the night through a Charity Raffle, with tickets being sold during the Champagne Reception, and the draw made by Dr David Reynolds, Chief Scientific Officer, Alzheimer's Research UK following his after dinner speech.

ARUK representatives will be onsite during the reception to provide details of the Raffle prizes and sell tickets.

2017 Award Categories

* Once you've reviewed the category finalists and chosen who you're voting for, use this page to note down the number attached to their profile in the boxes provided. You'll use these numbers with your keypads when the live voting begins.

Life Science Spin-Out of the Year
(<1 year from spin-out)

Hosted by

J A · K E M P

CRITERIA

Targeting of unmet need
Securing of initial funding / sources of funding
Level / reputation of investor(s) attracted
Ability to move candidates through pre-clinical stages
Seeding of industry partnerships
Strengthening of Scientific Advisory Board

Supporting information is attributed to a 1st June 2016 - 1st June 2017 timeline.

Achilles Therapeutics (1)

Immuno-Oncology

- Achilles Therapeutics design therapies to target truncal tumour neo-antigens – unique flags to the immune system present on the surface of every cancer cell.
- Syncona, an investment company and subsidiary of the Wellcome Trust, and Cancer Research Technology, with the support of UCL Business and the Crick, formed Achilles Therapeutics with a successful financing round of £13.2 million led by Syncona with the CRT Pioneer Fund and the UCL Technology Fund.
- A recent large scale Cancer Research UK study, TRACERx, which is led by the founders of Achilles, has found that unstable chromosomes within lung tumours increase the risk of cancer returning after surgery. The findings, which have been published in two prestigious medical research publications, the New England Journal of Medicine and Nature, reveal new insights into how tumours evolve and evade treatment, a leading cause of cancer death.
- TRACERx, is the first study to look at the evolution of cancer in real time in immense detail. Researchers followed patients all the way from diagnosis through to either disease relapse or cure after surgery, tracking and analysing how their cancer developed.

Apollo Therapeutics (2)

Drug Discovery

- Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, UCL and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). It provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.
- Apollo supports the translation of ground-breaking academic science from within these universities into innovative new drug discovery programmes and potential new medicines for a broad range of diseases. Since its launch, Apollo has approved funding for and launched initial discovery projects across antitrypsin deficiency, retinal degeneration, pulmonary arterial hypertension and the enhancement of autologous and in vivo T-cell therapies.
- The drug discovery team is lead by the CEO and are experienced in the discovery and development of pharmaceuticals from a range of modalities and therapeutic indications. The drug discovery team will work with academic scientist to identify the best translational targets and to prosecute and deliver a pipeline of targets for licensing.

Cardian (3)

Cardiac failure monitoring implants

- Touchstone Innovations plc, Imperial Innovations' parent company, provided £1.5 million seed investment round in Cardian
- Cardian was formed to commercialise a novel implantable device that improves the monitoring and treatment of cardiac failure patients, by providing automated, continuous wireless monitoring of blood pressure in the pulmonary artery. This fully implantable wireless pulmonary arterial pressure (PAP) sensor needs neither batteries nor a power line. The sensor is read by an external body-worn portable reader the size of a smartphone, in real time, 24/7, allowing the patient to undertake daily activities rather than lie in a hospital bed.
- The Company's newly appointed Chief Executive Officer, Sandeep Yadav was previously COO of Cardiomems, one of the pioneers of the monitoring of pulmonary arterial pressure.
- The underlying technology was developed by the Company's co-founders Dr Christopher McLeod, Dr Mohammad Reza Bahmanyar, and Dr Longfang Zou of the Institute of Biomedical Engineering and the Department of Electrical and Electronic Engineering at Imperial College.

Circadian Therapeutics (4)

Circadian rhythm modulating drugs

- Circadian Therapeutics, a life sciences spinout of Oxford University, has been established to identify and bring to market pharmaceutical and diagnostic platforms for the effective management of physiological and pathological conditions through their ability to modify the body's circadian rhythms.
- Circadian Therapeutics was established by Oxford University Innovation (OUI), the research commercialisation company of Oxford University. The company has raised £2m from Oxford Sciences Innovation (OSI), the patient capital investor for Oxford University. Dr Chris Blackwell, former CEO of Vectura Group, is Chairman of Circadian Therapeutics.
- Circadian's intellectual property draws on the input of the Nuffield Department of Clinical Neurosciences, the Department of Pharmacology, and the Institute of Biomedical Engineering, and builds on research supported by the Wellcome Trust.
- Circadian Therapeutics raised investment to fund development of their lead pre-clinical programme and will be looking to raise additional money to fuel proof-of-concept studies aiming to improve the lives of those impacted by disrupted circadian rhythms.

GammaDelta Therapeutics (5)

Immunotherapy

- GammaDelta Therapeutics Ltd, is a breakthrough Immunotherapy company incubated by Abingworth. The company is supported by Cancer Research Technology, King's College London and the Francis Crick Institute. Investment group.
- Abingworth provided the seed funding.
- GammaDelta Therapeutics has been founded on pioneering research by Professor Adrian Hayday and Dr Oliver Nussbaumer at King's College London and the Francis Crick Institute, funded in part by Cancer Research UK, into gamma delta (𝛾𝛿) T cells. These are a unique and conserved population of lymphocytes that contribute to many types of immune responses and immunopathologies. The new company is focused on exploiting this work to develop improved immunotherapies for cancer and potentially other diseases.
- Secured a $100m (£77m) collaboration with pharmaceutical giant Takeda to develop GammaDelta's novel T cell platform.
- Scientific Co-Founder, Professor Adrian Hayday, has received the inaugural Business of Science Leadership Award in recognition of his outstanding contribution to the field of gamma delta T Cell drug discovery.

Keapstone Therapeutics (6)

Parkinson's disease therapeutics research

- The University of Sheffield and Parkinson's UK have launched a new £1 million virtual biotech company in the next stage[1] of a pioneering research programme to create new drugs for Parkinson's.
- In a partnership that is the first of its kind, Keapstone Therapeutics will combine world-leading research from the University with funding and expertise from the charity to help develop revolutionary drugs for Parkinson's.
- Although similar partnerships between charities and research specialists have been formed in the past, this is the first time a charity has directly approached researchers to launch a spin-out company with the aim of advancing one particular research programme.
- The creation of Keapstone Therapeutics is part of Parkinson's UK's new Virtual Biotech venture, formed to combat the lost opportunities in drug discovery and early clinical development caused by the changing pharma landscape.
- The set-up means that Parkinson's UK and University of Sheffield will each retain a stake in future developments.

Microbiotica (7)

Human microbiome's role in disease

- Microbiotica develops and commercialise ground-breaking research into the role of the human microbiome in health and disease and its application to medicine conducted in the Host-Microbiotica Interactions Laboratory ("HMIL") at the world-renowned Wellcome Trust Sanger Institute, Cambridge. It received £8m funding from Cambridge Innovation Capital and IP Group.
- The Company has a strong leadership position in understanding how the microbiome can be used to not only develop new therapeutics for a range of diseases but also how to stratify patients according to their microbial profile, identify links with disease and exploit its full potential for human healthcare.
- Microbiotica has been granted unique access to these resources and capabilities and will use it to gain unparalleled insights into the microbial communities in both healthy and diseased individuals, enabling the identification of specific disease-related bacteria, patient-stratification strategies and novel therapeutics.
- Microbiotica has also been granted exclusive rights to existing potentially therapeutic bacterial mixes that have shown striking effects in novel models of disease, and which will be progressed into pre-clinical development over the coming year.

SuperX (8)

Anticoagulant antibodies

- SuperX takes a novel approach to specifically block the thrombosis that causes heart attacks and strokes, hoping to deliver the ideal anticoagulant treatment for chronic use. The SuperX team is engaged in the discovery of antibodies against an undisclosed target in the blood coagulation cascade.
- The $11m Series A investment was led by Medicxi to develop antibodies with anticoagulant properties. Johnson & Johnson Innovation - JJDC, Inc. (JJDC), the corporate venture arm of Johnson & Johnson, also participated
- Founded by Trevor Baglin, who will act as Chief Medical Officer at SuperX, together with David Grainger and Jim Huntington, SuperX reunites the entire management team that founded XO1 Ltd, which was acquired by Janssen Pharmaceuticals
- SuperX expects to begin clinical trials in 2018, and develop the product candidate for a range of indications where drugs such as warfarin, anti-platelet agents and novel oral anti-coagulants (NOACs) are currently used.
- SuperX is based on the Babraham Research Campus, just south of Cambridge, UK. It will operate as a virtual biotechnology company, with no internal operations, using an established network of out-sourced drug discovery and development providers.

Life Science Young Company of the Year (1-3 years old)

Hosted by

CLINIGEN Group plc

CRITERIA

Targeting of unmet need
Business model / strategy realisation
Securing of new funding / sources of funding
Ability to move candidates through pre-clinical / clinical stages
Creation of new partnerships / leveraging existing Partnerships
Strengthening of management team / Board

Supporting information is attributed to a 1st June 2016 - 1st June 2017 timeline.

Artios Pharma (1)

(DDR)-based cancer therapy

- Artios develops breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to selectively kill cancer cells. Artios aims to be the leading independent DDR company with a strong array of new cancer therapies in development. Our cutting-edge DDR programmes have potential applications across a broad range of cancers.
- Artios has in-licensed its lead DDR programme, PolO, from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK) and continues to work with CRT and other experts in the field to build its pipeline.
- Artios Pharma Ltd ("Artios" or "the Company") $33.2 Million Series A Financing from SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures to fund development of a DDR focussed pipeline
- Strengthened its management team with the appointment of Dr Simon Boulton as Vice President (VP) Science Strategy. Simon is an award-winning British scientist at the Francis Crick Institute in London who has made important contributions over the past 20 years to the understanding of DNA repair and the treatment of cancer resulting from DNA damage.

Auspherix (2)

Antibiotic development

- Auspherix ltd is an anti-infectives company engaged in the discovery and development of a new class of organogold-based antibiotics with a distinct antibacterial profile for serious and difficult to treat or potentially life-threatening infections.
- Auspherix's new class of antibiotics are differentiated from current antibiotics by their chemical structure and distinct antibacterial profile. Preliminary data indicates that Auspherix's organogold molecules show low propensity for the emergence of resistance.
- Lead optimization phase is on track to progress a development candidate from one of our three lead series into human clinical studies by early 2019, with an initial focus on treating complicated urinary tract infections (cUTI).
- WHO published its first ever list of antibiotic-resistant "priority pathogens" – a focused list of 12 families of bacteria that pose the greatest threat to human health. Auspherix's organogold compounds have shown activity against a number of the 12 pathogens on the WHO list, including all three critical threats
- Dr Neil Miller transitioned to Chief Executive Officer (CEO) from Chief Scientific Officer (CSO), and the Company announced two new appointments of Dr Richard Rutter as CSO and Dr Paul King as Head of Chemistry.

Autolus (3)

T-cell therapy

- Autolus is at the forefront of a revolution in cancer treatment. Chimeric Antigen Receptor (CAR) T-cell therapies have been shown to be effective in some haematological malignancies and may have wide applications as a cancer treatment, with the potential to offer a cure. Autolus is a leader in T-cell programming and manufacturing technology.
- Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to successfully manufacture, develop and commercialise T-cell therapies.
- Autolus collaborates with leading academic institutions and industry partners to develop and deliver transformative T-cell immunotherapy products to patients.
- New CAR-T Approach for the Treatment of T-Cell Lymphomas Presented at the December 2016 American Society of Hematology Annual Meeting.
- Data demonstrated that directing CAR-T cell therapy against a specific variant of TRBC has the potential to eliminate T cell lymphoma without eradicating the entire T cell compartment and thus preserving the patient's ability to fight viral disease.

BenevolentAI (4)

Pharmaceuticals

- BenevolentAI focuses on bioscience - increasing the understanding of human biology by ingesting the entire compendium of information on human health and biological systems.
- Partnered with MRC Technology ("MRCT"), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
- The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world's leading centres for research into Motor Neurone Disease, Alzheimer's and Parkinson's Disease, announced that its research into a drug candidate discovered by British artificial intelligence firm BenevolentAI has delivered positive results.
- Expanded its footprint in the United States by opening an office in New York City and has made two significant hires - Keith Hall, from Google, and Daniel Neil, from the Institute of Neuroinformatics.
- Dr Ian Churcher joins as VP of Drug Discovery and Preclinical development. Ian joins from GSK where he previously headed up a Discovery Performance Unit.

Freeline Therapeutics (5)

Gene Therapeutics

- Freeline is a biopharmaceutical company focused on the development and commercialisation of gene therapies for bleeding and other debilitating disorders based on a next-generation AAV gene therapy platform developed by Amit Nathwani, Professor of Haematology at UCL and CSO of Freeline Therapeutics.
- Freeline is advancing therapies based on next generation proprietary AAV vector platform through the clinic to registration. Gene therapy has the potential to transform lives for people with severe diseases by providing a safe, reliable source of enzymes to the blood.
- The lead programme in our pipeline is a gene therapy for the treatment of haemophilia B.
- The European Society for Gene and Cell Therapy (EGCST) recognised the Company's Founder and Chief Scientific Officer (CSO), Professor Amit Nathwani, with the Outstanding Achievement Award

Nightstar Therapeutics (6)

Therapies for inherited retinal dystrophies

- Nightstar Therapeutics is developing and testing new therapies in patients to treat serious retinal disease. The Company applies 100% of its resources and industry-leading expertise in gene therapy, ophthalmology R&D, and surgical delivery to developing novel treatments for the eye.
- The company's lead therapeutic candidate - NSR AAV-REP1 - is an AAV gene therapy advancing toward late-stage, pivotal clinical testing in patients with choroideremia.
- Nightstar Therapeutics commences first Phase I/II Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa.
- The gene therapy approach being used employs best in class innovation, using a viral vector known as adeno-associated virus (AAV) to deliver a codon-optimised copy of the retinitis pigmentosa GTPase regulator (RPGR) gene into cells of the eye, a first for clinical testing.
- Nightstar Therapeutics Expanded Leadership Team, Names Gregory Robinson, Ph.D., as Chief Scientific Officer
- Announced the appointment of Scott M. Whitcup, M.D, an Opthalmology Industry Veteran to its board of directors.

Orchard Therapeutics (7)

Gene therapeutics

- Orchard Therapeutics is a biotechnology company incorporated in September 2015 and dedicated to bringing transformative gene therapies to patients with serious and life-threatening orphan diseases.
- Our programmes will use the potential of ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in severe and life-threatening inherited disorders. We work in partnership with the world's leading research centres to harness the life-giving potential of gene therapy.
- Orchard Therapeutics Limited entered a new clinical manufacturing services agreement with PCT Cell Therapy Services, LLC ("PCT"), a Hitachi Group Company.
- Alliance with PharmaCell B.V. ("PharmaCell"), a leading Contract Manufacturing Organization (CMO) for Cell and Gene Therapies and Regenerative Medicine.
- Entered into a strategic alliance with Oxford BioMedica plc, a world-leading company in gene and cell therapy.
- Orchard Therapeutics and UCLA receive $20 million in latest round of funding from California's stem cell agency.

Tusk Therapeutics (8)

Immuno-oncology

- Tusk Therapeutics is a privately-held, immuno-oncology company, focused on discovering and developing unique therapeutic antibodies that harness the power of the immune system for the treatment of cancer.
- The Company has established a growing, diversified pipeline of antibodies against a selection of both novel and validated targets that play an important role in the immune response to cancer.
- CANCER RESEARCH TECHNOLOGY, Cancer Research UK's commercial arm, Tusk Therapeutics, an immuno-oncology company and UCL (University College London) have signed a licence and collaboration agreement to research, develop and commercialise an antibody-based therapeutic against a target that plays a key role in immune suppression in cancer.
- Entered into a three-year collaboration with CRT and UCL to part-fund a programme of preclinical work, led by Dr. Quezada, to evaluate candidate antibodies in various cancer models prior to initiation of formal preclinical and clinical development. At the end of the collaboration, Tusk Therapeutics will assume responsibility for accelerating the progress of selected antibody candidates into the clinic.

Life Science Growth Company of the Year (>3 years old)

CRITERIA

Targeting of unmet need
Business model / strategy realisation
Securing of new funding / sources of funding
Ability to move candidates through pre-clinical / clinical stages
Ability to move the business through key stages of strategic development
Creation of new partnerships / leveraging existing Partnerships
Strengthening of management team / Board

Supporting information is attributed to a 1st June 2016 - 1st June 2017 timeline.

Bicycle Therapeutics (1)

Cancer Therapeutics

- Bicycle Therapeutics is pioneering first in class therapeutics to treat cancer and other debilitating diseases based on its proprietary bicyclic peptides (Bicycles®) platform.
- Bicycle Therapeutics is rapidly advancing towards the clinic in 2017 in collaboration with Cancer Research UK (CRUK), with its lead programme using a Bicycle Drug Conjugate® to selectively deliver toxin to tumours.
- Successful completion of a £40 million Series B financing round. Proceeds will be used to further the development of multiple drug candidates, including Bicycle's lead molecule, BT1718, a first-in-class drug for cancers of high unmet need.
- Announced the receipt of a preclinical milestone in connection with the advancement of a Bicycle into preclinical development for the treatment of diabetic macular edema, under its ophthalmology alliance with ThromboGenics
- Entered into a collaboration with AstraZeneca for the identification and development of bicyclic peptides (Bicycles®) for the treatment of respiratory, cardiovascular and metabolic diseases.
-Announced an agreement to trial a first-in-class drug for cancers of high unmet need with CRUK and CRT

Cell Medica (2)

Cellular immunotherapy

- Cell Medica is committed to improving patients' lives through the significant therapeutic potential of cellular immunotherapy.
- Our approach is to apply innovative technologies with the aim of improving the treatment of cancer and immune reconstitution following hematopoietic stem cell transplant.
- Closed a £60 million Series C investment round with participation from existing investors Touchstone Innovations, funds managed by Invesco Perpetual, and funds managed by Woodford Investment Management.
- U.S. FDAhas granted Fast Track designation to its lead oncology product CMD-003 for patients with relapsed/refractory lymphoma and post-transplant lymphoproliferative disease associated with the oncogenic Epstein Barr virus (EBV).
- Cell Medica and Baylor College of Medicine expand partnership to develop allogeneic CAR-NKT cells for cancer treatment.
- European Commission orphan drug designations for CMD-003 (baltaleucel-T) as a treatment for extranodal NK/T-cell lymphoma
- Acquisition of Delenex Therapeutics AG, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics.

Crescendo Biologics (3)

Oncology Therapeutics

- Crescendo Biologics is a biopharmaceutical company discovering and developing potent, highly differentiated Humabody® therapeutics in Oncology. Humabody therapeutics are based on our proprietary, robust and highly efficient transgenic platform generating fully human VH domain building blocks (Humabody VH) with superior biophysical properties.
- We can rapidly assemble VH building blocks into an almost limitless number of optimally configured mono- and multi-specific Humabody therapeutics capable of engaging targets in ways that are fundamentally different from IgG.
- Partners with software-provider, Genedata, on next-generation immuno-oncology and ADC programs.
- Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m
- Strengthens IP portfolio with U.S. patent to transgenic mouse platform for generating Humabody® therapeutics.
- Appoints Theodora Harold as Chief Financial Officer
- Appoints Philip Bland-Ward as Chief Scientific Officer
- Nominated for Mediscience Emerging Star Award

F-Star (4)

Immuno-oncology

- F-star is a biopharmaceutical company focused on developing immuno-oncology bispecific antibody therapeutics.
- F-star Expands its Relationship with Merck through a new Strategic Collaboration to Develop Bispecific Antibodies in Immuno-Oncology. F-star to receive up to €115 million over the first two years. Merck has option to acquire the programmes, with potential deal value of over €1 billion
- Presents Preclinical Data at AACR 2017 on Tumour Growth Inhibition in Colon Carcinoma Models using Bispecific Antibodies. The data supports the preclinical development of FS118, F-star's anti-human LAG-3/PD-L1 mAb² for treatment of cancer patients.
- Announces Collaborative Agreement with Denali Therapeutics for the Development of a Multispecific Antibody Platform to Deliver Therapeutics across the Blood-Brain Barrier
- Announced the extension of a multi-year collaboration and funding arrangement with the newly opened Christian Doppler (CD) Laboratory for Innovative Immunotherapeutics at BOKU, the University of Natural Resources and Life Sciences in Vienna.
- Awarded "Life Science Innovation" Company of the Year by Business Weekly.

Immunocore (5)

Breaking new ground in immunotherapy

IMMUNOCORE

- Immunocore is the world's leading T cell receptor (TCR) company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, through its pioneering soluble TCR technology platform.
- Immunocore Highlights IMCgp100 clinical data in Uveal Melanoma at ASCO 2017 Annual Meeting
- Immunocore identifies second novel ImmTAC® in the GSK collaboration
- Immunocore Presents Positive Monotherapy Data in Uveal Melanoma at the Society for Melanoma Research (SMR) 2016 Congress
- Immunocore Ranked in the Sunday Times Hiscox Tech Track 100
- Immunocore's ImmTAV shown to redirect the immune system to kill HIV-infected cells from patients treated with antiretroviral therapy
- Immunocore Presents Positive IMCgp100 Phase I Data at the 2016 ASCO Annual Meeting

Kymab (6)

Antibodies

kymab

- We are a therapeutic antibody company, Based in Cambridge, UK, we're working with partners to provide novel solutions in drug and vaccine development. Unique technologies drive our rapid development of effective, human antibodies across our four main therapeutic areas - immuno-oncology, inflammation, haematology and infectious disease.
- Using our unique technology, we rapidly develop broad diversity, high quality human antibodies against challenging targets. With investment totalling $220m, we are using our Kymouse™ platform to help our partners to realise new opportunities in therapeutic and vaccine development.
- Kymab receives $9m grant from the Bill & Melinda Gates Foundation to fund infectious disease research and development
- Early stage results of its new antibody treatment, KY1005, showed an improvement in post-transplant survival in an animal model of acute graft-versus-host-disease (GvHD), a common and potentially deadly complication of bone marrow transplants.
- Secured a US$100 million (£81 million) Series C financing.
- Cross-licensing and development agreement with EpimAb to develop bispecific therapeutic antibodies against multiple targets.

MISSION Therapeutics (7)

DUBs

mission therapeutics

- Mission Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and other diseases of unmet need.
- Mission has built a World-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential 'Next Kinase Area'. Mission's DUB platform is yielding a rich pipeline of novel therapeutics.
- Mission Therapeutics and University of Oxford Awarded Research Grant from the Michael J. Fox Foundation. Supported the testing of Mission Therapeutics' potent and selective USP30-targeted inhibitors in translationally relevant stem cell-derived Parkinson's disease models developed by Prof Richard Wade-Martins and his research group at the University of Oxford.
- Chief Medical Officer, Dr Michael Koslowski has been listed as one of the 20 top translational researchers of 2015 in Nature Biotechnology. Based on the number of patents granted, the annual ranking of faculty is published in the bioentrepreneur section
- Appointment of Dr Anne Phelan as Senior Vice President, Head of Discovery Research

PsiOxus Therapeutics (8)

Immuno-oncology

PsiOxus THERAPEUTICS

- At PsiOxus, we aim to be the world-leading immuno-oncolytic virus company, delivering medicines of value to cancer patients.
- Our work is product and platform based with a focus on discovering and developing innovative oncolytic viruses for the treatment of solid tumors.
- Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an "Armed" Oncolytic Virus to Address Solid Tumors
- PsiOxus Therapeutics Licenses Immunotherapeutic Delivery Technology 'Polymap to Avidea Technologies.
- Appointment of Dr Charles "Charlie" Morris as Chief Development Officer and Karen LaRochelle as Chief Business Officer, both of whom will be based in the United States. These are the first C Level appointments in the US for the Oxford, UK based company as part of a planned expansion both in the UK and the US.
- Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev.

Private Finance Raise of the Year (≤£25m)

CRITERIA

Securing of significant new funds for growth / strategic development
Amount and source of funds raised
Level / reputation of investor(s) attracted
Addition of new or existing investors
Allocation of funds

Supporting information is attributed to a 1st June 2016 - 1st June 2017 timeline.

Achilles Therapeutics (1)

Immuno-Oncology

- Achilles Therapeutics' mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells.
-£13.2m, Seed Financing delivered over a number of tranches.
- Seed finance led by Syncona with the CRT Pioneer Fund and the UCL Technology Fund, with the support of UCL Business (UCLB) and the Crick.
- CRT will receive equity milestones and royalties from products developed and commercialised by Achilles Therapeutics. Any such financial reward from the company will be shared with UCLB and the Crick.

Apcintex (2)

Haemophilia therapy

ApcinteX
Effective and safe haemostasis

- ApcinteX, a University of Cambridge spin-out company, is seeking to disrupt the $10 billion haemophilia market by developing a drug that can be used in all patients, regardless of the type of haemophilia.
- This treatment is based on the work of Jim Huntington of the Cambridge Institute for Medical Research and Trevor Baglin of the Cambridge University Hospitals.
- £14m Series A round was co-led by Medicxi, a VC firm managing a €210m ($225m) fund backed by pharmaceutical firms GlaxoSmithKline and Johnson & Johnson and Touchstone Innovations Group plc (AIM: IVO), Touchstone Innovations, the commercialisation firm spun out of Imperial College London. Cambridge Enterprise helped in ApcinteX's formation, licensing key intellectual property to the company whilst also contributing to the round.
- The haemophilia market is estimated to be worth £8bn.

Artios Pharma (3)

(DDR)-based cancer therapy

artios
DNA DAMAGE RESPONSE

- Artios develops breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to selectively kill cancer cells. Artios aims to be the leading independent DDR company with a strong array of new cancer therapies in development. Our cutting-edge DDR programmes have potential applications across a broad range of cancers.
-£25m, Series A led by SV Life Sciences
- Additional investors included Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures
- The company intends to use the funds to build a pipeline of DDR therapies targeted against cancer and to progress its lead programme, Pol-theta, into the clinic.

Congenica (4)

Data solutions for genetic diagnosis

CONGENICA
GENOME BASED MEDICINE

- Congenica is a global company founded on pioneering research from the Sanger Institute based at the Wellcome Genome Campus in Cambridge. We've translated this research into the gold standard clinical genomic analytics platform, Sapientia®, providing integration of human DNA sequences with deep clinical phenotyping, enabling clinicians to provide actionable interpretation of genetic disease for patients.
- £8m, Series B, Cambridge Innovation Capital plc and Amadeus Capital Partners
- Additional new investor Parkwalk Advisors.
- Congenica will use the Series B investment to sustain the commercial roll out of its Sapientia clinical genome analysis platform, by accelerating international growth and expanding customer support. It will also invest in further product development and innovation.

NeRRe Therapeutics (5)

Neural hypersensitivity therapeutics

- NeRRe Therapeutics is a UK based clinical-stage company developing a unique portfolio of neurokinin (NK) receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity.
- The financing round involved a syndicate of leading transatlantic life sciences investors led by new investor Fountain Healthcare Partners, and co-led by Forbion Capital Partners and OrbiMed.
- Existing investors, Advent Life Sciences and Novo A/S participated.
- The funds will be used by NeRRe to generate Phase 2 data on orvepitant, its lead oral NK-1 antagonist candidate as a potential new treatment for a common, chronic respiratory condition; and to advance NT-814, a dual NK-1,3 antagonist, into Phase 2 trials as a potential non-hormonal treatment of distressing post-menopausal vasomotor symptoms.

Oxular (6)

Retinal therapeutics

- Oxular is pioneering an approach that offers tailored drug distribution and a likely reduction in side-effects, by virtue of the fact that the active drug will not contact the whole eye.
- Our approach packages the drugs in a novel form that allows easy administration, ocular distribution and controlled release. We believe Precision Ocular has the potential to develop a platform technology with broad applicability.
- £15.5m, oversubscribed Series A, Imperial Innovations, Consort Medical plc, NeoMed, V-Bio Ventures, and Hovione Scientia Ltd.
- The company intends to use the funds to develop programs to treat retinal diseases such as age related macular degeneration and diabetic macular oedema, as well as rare and orphan indications, and enable the development of next generation ocular drug delivery systems which can administer cell and gene therapies to the back-of-eye.

Pulmocide (7)

Respiratory Infection

- Pulmocide is a unique biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients' quality of life.
- Unlike currently available treatments for fungal and viral infections in the lung, our innovative approach to drug development provides targeted delivery to the lung so that infections can be treated with minimal unwanted systemic effects.
- £24m, Series B, led by new investor SR-One, included Longwood Fund plus existing investors SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. and Touchstone Innovations plc.
- The proceeds will enable Pulmocide to progress its wholly-owned assets through early clinical development. Pulmocide is on track to deliver proof of concept data in RSV with its highly potent inhaled RSV antiviral agent (PC786) in human RSV challenge and in infants hospitalised with bronchiolitis due to RSV infection.
- Pulmocide will also be progressing PC945, a potent azole antifungal for the treatment of pulmonary Aspergillosis, including fungal asthma, pulmonary Aspergillom

Private Finance Raise of the Year (>£25m)

CRITERIA

Securing of significant new funds for growth / strategic development
Amount and source of funds raised
Level / reputation of investor(s) attracted
Addition of new or existing investors
Allocation of funds

Supporting information is attributed to a 1st June 2016 - 1st June 2017 timeline.

Atlas Genetics (1)

Ultra rapid diagnostics

- Our pioneering, flexible diagnostic instrument and disposable cartridge system is designed for decentralised laboratory, point-of–care and other near-patient settings. It provides a fast, easy-to-use and accurate affordable solution to screening for the presence of STIs and HAIs, where rapid diagnosis is essential for effective treatment and control.
£28.3m, Series D, new investor Wondfo Biotech alongside existing investors Novartis Venture Funds, Consort Medical plc, J&J LSP, BB Biotech Ventures, RMI Partners and Technology Venture Partners, YFM Equity Partners.
- This new Series D equity issue will finance the clinical trials and commercial launch of a second test, for detection of both Chlamydia and Gonorrhoea, planned for regulatory approvals in the US around the end of 2017, as well as further development of additional diagnostics menu. The financing also provides funding to expand cartridge manufacturing capacity at Bespak, Atlas Genetics' cartridge manufacturing partner.

Bicycle Therapeutics (2)

Cancer Therapeutics

- Bicycle Therapeutics is pioneering first in class therapeutics to treat cancer and other debilitating diseases based on its proprietary bicyclic peptides (Bicycles®) platform. Bicycles are a breakthrough new therapeutic class that combine antibody-like affinity and selectivity with small molecule-like tissue penetration, tuneable exposure, flexible pharmacokinetics and chemical synthesis.
- £40m, Series B, new investor Vertex Ventures HC led the financing round alongside participation by additional new investors Cambridge Innovation Capital (CIC) and Longwood Fund
- Existing investors – Novartis Venture Fund, SROne, SVLS and Atlas Venture also participated
- Proceeds will be used to further the development of multiple drug candidates, including Bicycle's lead molecule, BT1718, a first-in-class drug for cancers of high unmet need.
- As part of this financing, the company also announced the addition of Dr. Christopher Shen, M.D., Managing Director at Vertex Ventures HC, and Dr. Michael Anstey, D.Phil., Investment Director at CIC, to its Board of Directors.

Carrick Therapeutics (3)

Cancer

- Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer. In doing so, we aim to have a major impact on the lives of patients with the greatest unmet need and transform the way that cancer is treated.
- £74m, Series A, led by ARCH Venture Partners and Woodford Investment Management. Investors include Cambridge Enterprise, Evotec AG, Google Ventures, Lightstone Venture and Cambridge Innovation Capital.
- This funding is one of the largest early stage investments in a European university spin-out.
- In conjunction with the funding, Steven Gillis and Paul Thurk, ARCH Venture Partners, and Jason Lettmann, Lightstone Ventures, joined CEO Elaine Sullivan on the Carrick board of directors.
- The company is now working on three innovative scientific programs, and is looking to expand its portfolio through academic and pharmaceutical partnerships.

Cell Medica (4)

Cellular immunotherapy

- Cell Medica is committed to improving patients' lives through the significant therapeutic potential of cellular immunotherapy. Our approach is to apply innovative technologies with the aim of improving the treatment of cancer and immune reconstitution following hematopoietic stem cell transplant.
- £60m, Series C, Participation from existing investors Touchstone Innovations, funds managed by Invesco Perpetual, and funds managed by Woodford Investment Management.
- Cell Medica will use the investment capital to continue to progress its three proprietary technology platforms for cell-based immunotherapy products. The Company's lead oncology product, baltaleucel-T (CMD-003), is currently under investigation in the CITADEL Phase 2 clinical trial for the treatment of patients with advanced lymphomas associated with the Epstein Barr virus.

F2G (5)

Antifungal pharmaceuticals

Advancing Antifungal R&D

- F2G is an established UK Biotech focusing on the discovery and development of novel drugs to treat life threatening fungal diseases. Fungal infection typically affects the immune-compromised patient where mortality rates are often very high. The focus at F2G is to serve the current unmet medical need by developing drugs that target the most difficult to treat fungi, especially those with the highest mortality rates.
- £46.5m, Series E, led by Sectoral Asset Management, with participation from Novo A/S, Aisling Capital and Brace Pharma Capital. Existing investors Advent Life Sciences LLP, Novartis Venture Fund, Sunstone Capital and Merifin Capital each participated in the round.
- Financing to progress development of novel antifungal agents and to take lead compound through to product approval and development of pipeline assets.

Kymab (6)

Antibodies

- We are a therapeutic antibody company, Based in Cambridge, UK, we're working with partners to provide novel solutions in drug and vaccine development. Using our unique technology, we rapidly develop broad diversity, high quality human antibodies against challenging targets. With investment totalling $220m, we are using our Kymouse™ platform to help our partners to realise new opportunities in therapeutic and vaccine development.
- Kymab - £78m, Series C, led by new investors ORI Healthcare Fund, with participation by Shenzhen Hepalink Pharmaceutical and follow-on investments from existing shareholders Wellcome Trust, Bill & Melinda Gates Foundation, Malin Corporation, CF Woodford Equity Income Fund and Woodford Patient Capital.
- The funds will enable Kymab to advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies, the first of which is commencing clinical development in 2017.

Oxford Nanopore (7)

Nanopore DNA Sequencer

- Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
- £100m, Venture Financing, led by new investor GT Healthcare Healthcare Partners, an investment partnership based in Hong Kong, alongside existing UK-based shareholders Woodford Investment Management and IP Group Plc.
- The new funds will be used to expand the firm's commercial operations across a range of territories, including Asia, ramp-up production and sales and marketing capability for its existing products, and further develop and expand its innovative pipeline, including the mobile-phone compatible SmidgION sequencer.

Life Science IPO of the Year

CRITERIA

Amount and source of funds raised / market cap valuation
Value creation / value realisation
Post-listing share performance
Allocation of funds

Supporting information is attributed to a 1st June 2016 - 1st June 2017 timeline.

Convatec (1)

Medtech **Chronic Disease**

- ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices.
- ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.
- £1,465m raise, issue price 225p (CTEC:LSE)
- Market cap based on the IPO was £4.4bn
- Share price High 325.50p during qualifying period
- Share price at 31st May 2017, 320p
- New products the company is focusing on include the next generation of anti-microbial technologies and negative-pressure wound therapy, a market valued at about $1.7 billion.

CREO Medical (2)

Electrosurgery

- CREO Medical's vision is to develop and commercialise a suite of products based on the CROMA electrosurgery platform, initially launching this energy system into the flexible endoscopy market that includes GI endoscopy and bronchoscopy. In addition, the long term intention is expand into other adjacent markets, either organically, through partnership or acquisition.
- £20m raise, issue price 76p (CREO:LSE)
- Market cap based on the IPO was £61.3m
- Post IPO High 113p during qualifying period
- Share price at 31st May 2017, 85p
- Company remains on track to initiate the soft launch of the Speedboat product later this year, in line with strategy at IPO to translate this surgery sparing technology into routine clinical practice and expect this to be followed by the introduction of a range of devices for the therapeutic endoscopy market. Surgical endoscopy, a billion dollar plus market, is an emerging field and with the CROMA platform and range of endoscopic devices.

Medica Group (3)

Radiology

- Through our NightHawk, DayHawk, and Routine services, we are the leading independent UK provider of radiology reporting, delivering in excess of 1.3 million reports a year.
- Our reputation has been built on the provision of high-quality, fast and cost-effective teleradiology reporting services with our clients' needs at the centre of everything we do.
- £121m raise, issue price 135p (MGP:LSE)
- Market cap based on the IPO was £150m
- Post IPO High 227.50p during qualifying period
- Share price at 31st May 2017, 222.50p
- The listing provides an opportunity for Medica to extend its healthcare offering into new areas by leveraging the company's key skill sets of high-quality clinical governance and utilising technology to increase efficiency.

Oxford BioDynamics (4)

Biomarkers

- Oxford BioDynamics are a biotechnology company with a proprietary biomarker discovery platform, EpiSwitch™, based on the latest advances in gene expression, non-coding RNA and epigenetics.
- Episwitch™ biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine. Technology to select the right drug at the right dose at the right time for the right patient.
- £20m raise, issue price 158p (OBD:LSE)
- Market cap based on the IPO was £136m
- Post IPO High 160p during qualifying period
- Share price at 31st May 2017, 140p
- Of the £20m raised in the IPO, £12.9m went to existing shareholders as they realise their investments, while £7.1m will be used to drive growth.

SkinBioTherapeutics (5)

Skin Health

- SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain at The Univ. of Manchester.
- The SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.
- £4.5m raise, issue price 9p (SBTX:LSE)
- Market cap based on the IPO was £13.35m
- Post IPO High 16p during qualifying period
- Share price at 31st May 2017, 12.25p
- Rationale for the IPO and funding is to drive the development and future commercialisation of SkinBioTherapeutics' SkinBiotix® technology platform.

Verona Pharma (6)

Respiratory therapeutics

- Verona Pharma plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.
- Our proprietary lead candidate, RPL554, is paving the way for a new generation of drugs, with a novel mode of action, and has the potential to provide relief for the many patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and possibly asthma.
- $78m raise, issue price $13.50 (VRNA:US NASDAQ)
- Market cap based on the IPO was $163m
- Post IPO High $16.26 during qualifying period
- Share price at 31st May 2017, $13.95
- Supported commencement off four clinical trials with our lead candidate RPL554, including first clinical study in the United States following FDA acceptance of IND application and have continued to expand senior management.

Widecells Group (7)

Cord Blood **Stem Cell**

- We are leading a transformation in cord blood banking and stem cell treatment; making cord blood banking more accessible through insurance coverage, and increasing the availability of cord blood for transplants.
- WideCells Group PLC blends a unique business model with an expert team to bring promising cord blood banking and stem cell therapy from the lab to the real world of family healthcare protection. We founded WideCells Group PLC to leverage that expertise to create a truly unique, wholly sustainable group of companies.
- £2m raise, issue price 11p (WDC:LSE)
- Market cap based on the IPO was £6m
- Post IPO High 16.25p during qualifying period
- Share price at 31st May 2017, 11.88p
- The £2min raised is being used for marketing and to set up a stem storage facility in Manchester.

Public Finance Raise of the Year (non-IPO)

CRITERIA

Securing of significant new funds for growth / strategic development
Amount and source of funds raised
Post-finance performance
Allocation of funds

Supporting information is attributed to a 1st June 2016 - 1st June 2017 timeline.

Abzena (1)

Biopharmaceuticals

- Abzena incorporates the businesses of Antitope, PacificGMP, PolyTherics, The Chemistry Research Solution (TCRS) and Warwick Effect Polymers, all of which now trade as Abzena. Abzena has over 40 technology licence and option agreements covering its proprietary antibody drug conjugate (ADC) linker, antibody humanization, and protein deimmunisation technologies. The linker technology produces more stable and homogenous ADCs.
- £25m raised to expand further its service offering, capacity and capabilities.
- A total of 75,757,576 new ordinary shares of £0.002 each in the Company representing approximately 55.0 per cent. of the Company's existing issued ordinary share capital have been conditionally placed at a price of 33 pence per Placing Share.
- Placing share price, 33p. Share price at 31 May 2017, 38.9p
- Abzena will use the net proceeds of the Placing to drive additional growth in the business, which the Board believes can create critical mass and enable the Group to capitalise on significant cross selling opportunities across its complementary service and technology offerings.

C4X Discovery (2)

Drug discovery

- C4X Discovery aims to become the world's most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. The Company has two proprietary and synergistic software platforms "Taxonomy3®" and "Conformetrix".
- £7m raised to continue to build its existing pipeline of five preclinical assets.
- Placing of up to 8,235,294 new ordinary shares in the capital of the Company, representing approximately 22.0% of the Company's existing ordinary share capital.
- Placing share price, 85p. Share price at 31 May 2017, 87p
- The net proceeds of the Placing receivable by the Company will be used to support the execution of its strategy of becoming the world's most productive, self-sustaining drug discovery engine by strengthening its balance sheet as partnering discussions and strategic collaborations progress, expanding its commercial capability and supporting working capital during the expansion of its pipeline portfolio.

Genedrive (3)

Molecular diagnostics at the point of need

- A pioneering molecular diagnostic system, Genedrive® provides rapid and accurate genotyping and sequence analysis from various sample types. Robust and affordable, the system is ideal for use in high burden disease markets.
- Current tests on the Genedrive® system include Genedrive® MTB/RIF ID Kit for the simultaneous detection of Mycobacterium tuberculosis and rifampicin resistance, and Genedrive® IL28B ID Kit for the rapid detection of Interleukin 28B genotyping status.
- £6.5m raised to broaden the portfolio of its Genedrive tests, developed to fight infectious diseases.
- Placing of 8,125,000 new Ordinary Shares in the capital of the Company.
- Placing share price, 80p. Share price at 31 May 2017, 40.98p
- The successful fundraising puts the company in strong position to deliver on the diagnostics platform's potential and expand its testing capabilities.

Midatech Pharma (4)

Pharmaceuticals

- An international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas. Midatech is commercialising oncology treatment and supportive care products through its US commercial organisation, Midatech Pharma US ("Midatech US") (formerly DARA BioSciences, Inc.).
- In Europe, Midatech is developing a pipeline of product candidates in clinical and pre-clinical development for diseases for which there are currently few or no treatment options available.
- £16m raised to expand and advance its oncology-focused development pipeline
- Placing of 14,545,455 shares, representing approximately 43.4%. of the existing ordinary shares of the Company.
- Placing share price, 110p. Share price at 31 May 2017, 106.5p
- The net proceeds of the placing will be used to invest in expanding and advancing its development pipeline, including for Q-Octreotide MTD 201 and its MTX 110/MTX 111 treatment for DIPG, in addition to investing in its manufacturing and commercial platform and providing additional working capital to the group.

Oxford BioMedica (5)

Gene and cell therapy

- Oxford BioMedica is a world leading gene and cell therapy company focused on developing life changing treatments for serious diseases. We have built a platform of exclusive cutting-edge technologies and capabilities, based on a sector leading and proprietary single dose gene therapy platform (LentiVector®), with which we design, develop and produce gene and cell based medicines for ourselves and for our partners.
- £10m raised to fund progress on its discovery and pre-clinical projects
- Issue of 184,255,000 New Ordinary Shares by means of a placing (the "Placing") and 199,116,665 New Ordinary Shares by means of a subscription
- Placing share price, 3p. Share price at 31 May 2017, 5p
- The new funds raised will enable the company to progress the discovery and pre-clinical projects, develop valuable intellectual property relating to the LentiVector® platform and provide working capital for the Group to generate demand for the bioprocessing capabilities that will accelerate the growth of revenues.

Scancell Holdings (6)

Cancer immunotherapy

- A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body's own natural defence mechanism - the immune system. Scancell's mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer. Founded in 1997 as a spin-out from the University of Nottingham, Scancell has secured £23 million funding to date.
- £5m raised to fund clinical work on its pipeline of cancer immune-therapies
- Issue of 50,499,999 Shares at a Placing Price of 10p per Placing Share. The Placing Shares represent approximately 19.3 per cent. of the existing Ordinary Shares of the Company.
- Placing share price, 10p. Share price at 31 May 2017, 10.5p
- The net proceeds of the Placing of approximately £4.7 million (after fees and expenses) will be used to support the Company's clinical development pipeline of novel cancer immunotherapies, in particular to initiate clinical development of the first product from the Moditope® platform, Modi-1, and to continue to support the pipeline arising from the ImmunoBody® platform.

Verona Pharma (7)

Respiratory therapeutics

- Verona Pharma plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.
- £44.7m raised to fund RPL554 through a phase 2b clinical trial in chronic obstructive pulmonary disease (COPD) patients and additional phase 2 studies in both COPD and cystic fibrosis.
- Issue of 1,555,796,345 shares at a price of 2.873 pence per ordinary share.
- The funds raised from the placing will allow the company to focus on conducting a comprehensive Phase 2b clinical trial programme for nebulised RPL554 as a potential treatment for patients with COPD. We will also explore in the clinic for the first time the use of RPL554 as a novel treatment for cystic fibrosis expanding the potential of the drug into another respiratory disease where there remains a significant unmet need.

Public Life Science Company of the Year

Hosted by

CMS

Law . Tax

CRITERIA

Business model / strategy realisation
Securing of new funding / sources of funding
Ability to move candidates through pre-clinical / clinical stages
Ability to move the business through key stages of strategic development
Recent transactions and deals / post-deal performance
Creation of new partnerships / leveraging existing Partnerships
Share price movement

Supporting information is attributed to a 1st June 2016 - 1st June 2017 timeline.

Abzena (1)

Biopharmaceuticals

- Abzena has over 40 technology licence and option agreements covering its proprietary antibody drug conjugate (ADC) linker, antibody humanization, and protein deimmunisation technologies.
- New 'Abzena inside' product entered Phase I clinical development with an undisclosed, private US biotech company – now 12 clinical stage products in 'Abzena inside' portfolio.
- Two 'Abzena inside' products progressed into Phase II clinical development: Roche's RG6125 for rheumatoid arthritis, and an undisclosed major US pharma programme for neurodegenerative conditions.
- Significant licence agreement for ThioBridge™ antibody drug conjugate (ADC) linker technology with San Diego-based biopharmaceutical company announced on 20 January 2017.
- Composite Human Antibody licence deal signed with public US biotech with potential to deliver $19m milestone payments
- £25m raised in share placement to expand further its service offering, capacity and capabilities.
- Share price on 1st June 2016, 47p, 1st June 2017, 40p.

Adaptimmune (2)

Cancer

- Adaptimmune, a leader in T-cell therapy to treat cancer, has multiple trials ongoing in both solid tumours and hematologic cancer types, and in cancers where survival rates for patients can be very limited.
- Completed April 2017 registered direct offering to Matrix Capital Management Company, LP, which combined with March 2017 public offering, raised total net proceeds of $103.2 million
- Initiated AFP SPEAR T-cell therapy clinical trial in hepatocellular carcinoma
- Initiated MAGE-A4 SPEAR T-cell therapy clinical trial in urothelial (bladder), melanoma, head & neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, and gastric cancers
- Initiated clinical trial of NY-ESO SPEAR T-cells in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 inhibitor marketed by Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), in patients with multiple myeloma.
- Share price on 1st June 2016, USD$14.82, 1st June 2017, USD$5.29.

AstraZeneca (3)

Pharmaceuticals

- A global pharmaceutical company with a major UK presence. Our purpose is to push the boundaries of science to deliver life-changing medicines.
- Continued to deliver transformative science across the pipeline, particularly in Oncology. Imfinzi was launched in bladder cancer while we published practice-changing data in breast cancer for Lynparza, our first-in-class PARP inhibitor. In lung cancer, we strengthened our unique portfolio focused on both the genetic drivers of disease and immunotherapy. In the first half, we shared positive results for Imfinzi in the PACIFIC trial and reported more encouraging data for Tagrisso in patients with central nervous system metastases.
- Regulatory approvals: Imfinzi (durvalumab) - bladder cancer (US), Faslodex - breast cancer (1st line) (EU, JP) and Kyntheum (brodalumab) - psoriasis (EU, received by partner)
- Regulatory submission acceptances: Lynparza - ovarian cancer (2nd line) (EU, JP) and Bevespi - COPD (EU)
- Share price on 1st June 2016, £40.15p, 1st June 2017, £53.28p.

Clinigen (4)

Pharmaceuticals

- Clinigen is a rapidly-growing specialty pharmaceutical and service company with a unique business model dedicated to delivering the right medicine to the right patient at the right time to improve the quality of people's lives around the world.
- Clinigen achieves positive CHMP opinion concerning Cardioxane in Europe.
- Clinigen and TESARO partner to initiate EU Managed Access Program for niraparib for patients with recurrent ovarian cancer.
- Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma
- First-in-class Fycompa® (perampanel) approved in South Africa for partial-onset seizures.
- Clinigen and Cumberland Pharmaceuticals enter exclusive U.S. commercialisation agreement for Totect®.
- Clinigen and BTG extend global partnership with new exclusive Global Access agreement.
- Clinigen launches Japanese business to strengthen Asian presence.
- Gross profit* expected to be up 22% driven by a combination of organic growth across all operations.
- Share price on 1st June 2016, £5.57p, 1st June 2017, £8.92p.

Horizon Discovery (5)

DNA sequencing and personalised medicine

- Translational genomics company developing and supplying patient-relevant drug discovery tools, diagnostic reference material.
- Introduces four BRAF resistant melanoma PDX models.
- Announces New Gene Editing Technology Platform for Research and Therapeutic Applications.
- Agreement with a Leading Global Molecular Diagnostics Provider for Reference Standards for Non-Invasive Prenatal Testing.
- Enters into R&D and licensing partnership with Amplycell S.A. for bioproduction cell line optimisation.
- Signs a Master Service Agreement with a Top Three Pharmaceutical Company.
- Broadens industry-leading gene editing capabilities through extension of key CRISPR license and grant-funded research.
- Horizon Discovery and Fulcrum Therapeutics Form Collaboration for Novel CRISPR-Based Target Discovery in Genetic Diseases.
- Horizon Discovery Group and Ventana Medical Systems Sign Co-development Agreement for Reference Standards.
- Horizon Discovery Takes Exclusive License to a Range of Melanoma Patient-Derived Xenograft Models.
- Share price on 1st June 2016, £1.73p, 1st June 2017, £1.94p.

Oxford BioMedica (6)

Gene and cell therapy

- Oxford BioMedica is a world leading gene and cell therapy company focused on developing life changing treatments.
- Novartis partnership progressed well with the BLA for Novartis' potential blockbuster product CTL019 granted priority review in paediatric and young adult patients with relapsed and refractory (r/r) B-cell acute lymphoblastic leukaemia; approval anticipated following unanimous vote at FDA advisory committee.
- Novartis received encouraging CTL019 Phase II results in r/r diffuse large B-cell lymphoma adding further major potential indication with breakthrough designation.
- Major new lentiviral vector supply agreement signed with Novartis for CTL019 and other undisclosed CART products; over $100 million revenue potential over three years including $10 million upfront payment.
- MHRA licence granted to the Group for commercial manufacture and supply of lentiviral vector.
- £2 million Innovate UK collaboration to further enhance LentiVector® platform suspension technology.
- Share price on 1st June 2016, £0.05p, 1st June 2017, £0.05p.

Shield Therapeutics (7)

Hospital-Focused Pharmaceuticals

- Shield Therapeutics is a well-funded, high potential, commercial stage specialty-pharma company. The Company's key products are Feraccru and PT20, one commercially available and one late-stage pharmaceutical for the treatment of iron deficiency anaemia and systemic phosphate accumulation (otherwise known as hyperphosphatemia), respectively.
- Marketing authorisation achieved across the EU for Feraccru® with first sales recorded in the UK and Germany.
- Feraccru® achieved attractive price points in the UK and Germany.
- First commercial product shipments completed to Central & East European Commercialisation partner, AOP Orphan Pharma
- New Composition of Matter patent granted for Feraccru®, extending the protection to mid 2030s.
- AEGIS-H2H and AEGIS-CKD Phase 3 studies progressing well with data anticipated towards the end of 2017 and positive data expected to facilitate broader commercialisation in Europe and NDA filing in the USA.
- Positive discussions with further licensing partners for Feraccru® in non-core markets.
- Share price on 1st June 2016, £1.775p, 1st June 2017, £1.685p.

Summit Therapeutics (8)

Drug Discovery

- Summit is advancing new therapies for the treatment of rare diseases and infectious diseases.
- Ezutromid, our lead utrophin modulator for DMD, achieved an important development milestone following completion of enrolment into our clinical trial called PhaseOut DMD, triggering a $22 million payment from our licence and collaboration partner Sarepta Therapeutics.
- Ridinilazole, our highly selective and potent antibiotic for the treatment of C. difficile infection, also continues to progress as we prepare the asset to start Phase 3 clinical trials in the first half of 2018.
- Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit's Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy, receiving $40m upfront.
- Completed enrolment into PhaseOut DMD in May 2017, which triggered a $22.0 milliondevelopment milestone payment.
- Summit Receives Rare Pediatric Disease Designation from US FDA for Ezutromid in Treatment of DMD.
- Share price on 1st June 2016, £1.10p, 1st June 2017, £1.75p.

Life Science Deal of the Year

CRITERIA

Uniqueness or novelty of deal strategy
Level of value creation / size of deal
Strength of partner / partnership and deal terms
Post-deal performance / shareholder ROI
Potential game / industry changing implications within next 12-months

Supporting information is attributed to a 1st June 2016 - 1st June 2017 timeline.

Abzena and OBI Pharma (1)

Biopharmaceuticals

- Signed a licensing agreement with San Diego-based biopharmaceutical company OBI-Pharma.
- The licensing agreement is for Abzena's novel site-specific ThioBridge™ antibody drug conjugate (ADC) linker technology to develop OBI's proprietary ADC, OBI-999 and a series of further ADCs as potential treatments for cancer.
- The agreement covers the use of ThioBridge™ in up to 10 ADCs across a wide range of indications. Abzena has also entered a master services agreement, which enables multiple programmes of work to be undertaken over an extended period, relating to the Group's chemistry services.
- OBI will receive a worldwide exclusive licence to use the ThioBridge technology to research, develop and commercialize ADCs targeting the Globo series. Abzena will receive a small initial up-front payment from OBI and has the potential, subject to successful development, to receive up to £128 million, in aggregate, which may become payable upon achievement of certain development, regulatory and commercialisation milestones.
- Abzena will also receive royalties on sales of any approved ADC products that incorporate the ThioBridge™ technology.

Bicycle Therapeutics and AstraZeneca (2)

- Entered into a collaboration with AstraZeneca for the identification and development of bicyclic peptides (Bicycles®) for the treatment of respiratory, cardiovascular and metabolic diseases.
- Under the terms of the agreement, Bicycle is responsible for identifying Bicycles® for an undisclosed number of targets specified by AstraZeneca while AstraZeneca is responsible for further development and product commercialization.
- The bicycle platform expands AstraZeneca's drug discovery capabilities and enables them to broaden the range of targets we they can prosecute across a range of disease indications.
- If all planned programmes reach the market, Bicycle will be eligible for over $1 billion in payments, including an upfront payment, future R&D funding, development, regulatory and commercialization milestone payments. - Bicycle would also be entitled to receive royalties on sales of products resulting from the collaboration.

Crescendo Biologics and Takeda (3)

- Announced a global, strategic, multi-target collaboration and license agreement for the discovery, development and commercialization of Humabody® -based therapeutics for cancer indications with a high unmet medical need.
- Crescendo will use its proprietary transgenic platform and engineering expertise to discover and optimally configure Humabody® candidates (Humabody® Drug Conjugates and Immuno-Oncology modulators) against multiple targets selected by Takeda.
- Crescendo is eligible to receive up to $36 million, in a combination of an upfront payment, investment, research funding and preclinical milestones.
- Takeda will have the right to develop and commercialize Humabody®-based therapeutics resulting from the collaboration.
- Crescendo is also eligible to receive further clinical development, regulatory and sales-based milestone payments of up to $754 million.
- In addition, Crescendo will be eligible to receive royalties on Humabody®-based product sales by Takeda.

F-Star and Merck (4)

- F-star Expands its Relationship with Merck through a new Strategic Collaboration to Develop Bispecific Antibodies in Immuno-Oncology.
- New strategic collaboration to develop and commercialise five bispecific immunooncology antibodies, including F-star's lead asset FS118.
- Upon option exercise, in addition to FS118, F-star grants Merck exclusive development and commercial rights to four novel bispecific antibodies targeting specific pathways to augment the anti-tumour immune response.
- Merck will pay up to €115m in upfront, R&D funding and milestone payments in the first two years, and make further payments upon exercising its option and based on milestones.
- This collaboration with Merck is held within F-star's fourth asset centric vehicle, F-star Delta. Upon the delivery of a pre-defined data package, Merck has an option to acquire the bispecific programmes through the acquisition of F-star Delta and will make further payments upon option exercise as well as milestones with the potential total deal value reaching over €1 billion.

GammaDelta Therapeutics and Takeda (5)

- Announced that they have formed a strategic collaboration to develop GammaDelta Therapeutics' novel T cell platform, which is based on the unique properties of gamma delta T cells derived from human tissues. The companies intend to use this novel platform to discover and develop new immunotherapies, with the aim of treating a broad range of cancers, including solid tumours, and autoinflammatory diseases.
- Takeda, together with Abingworth, will commit up to $100 million in funding to accelerate GammaDelta Therapeutics led Research and Development.
- The funding includes an equity investment, an option fee and research and development funding, and provides Takeda the exclusive right to purchase GammaDelta Therapeutics. Under the agreement.
- Takeda will appoint a director to GammaDelta Therapeutics' board.

PsiOxus Therapeutics and BMS (6)

- Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an "Armed" Oncolytic Virus to Address Solid Tumors.
- The NG-348 virus uses PsiOxus' proprietary Tumor-Specific Immuno-gene Therapy (T-SIGn) platform to "arm" the virus with two additional immuno-therapeutic transgenes.
- Under the terms of the agreement, Bristol-Myers Squibb will grant PsiOxus a $50 million upfront payment and will be solely responsible for global clinical development and commercialization activities related to NG-348.
- PsiOxus iseligible to receive up to $886 million in development, regulatory and sales-based milestones, as well as royalties on net sales.
- Bristol-Myers Squibb will be responsible for providing PsiOxus funding to support activities related to the preclinical development of NG-348.

Summit Therapeutics and Sarepta Therapeutics (7)

- Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit's Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy.
- Utrophin modulation is a potential disease-modifying treatment for all patients with the fatal muscle wasting disease DMD, regardless of their underlying dystrophin gene mutation.
proof of concept trial called PhaseOut DMD.- Sarepta and Summit collaborate to advance the development of novel therapies for patients with Duchenne muscular dystrophy
- Summit receives $40 million upfront, with potential future ezutromid-related milestone payments totalling up to $522 million plus royalties
- Sarepta and Summit to share research and development costs
- Sarepta also receives option for Latin American rights

Vectura and Skyepharma (8)

- Vectura agreed to buy Skyepharma in a £441.3m deal.
- Company is estimated to have a market capitalisation of just over £1 billion based on each respective valuation, with joint sales of £153.9 million and profits of around £50.5 million.
- An all share merger of Vectura and Skyepharma was completed in June 2016.
- The merger of Vectura and SkyePharma is a key milestone in the execution of our strategy to become a leading specialty pharmaceutical company, focusing on airways-related disease.
- Addition of SkyePharma's pMDI technology will allow the enlarged group to access the inhaled product market in its entirety
- Skyepharma shareholders got 2.79 Vectura shares for every share they owned, equivalent to 410.15p per share – a near-14 per cent premium to the current share price.
- Vectura boosted by Skyepharma merger. Interim results reveal rapid revenue growth powered by the merger which brought in an extra 13 royalty-earning marketed products.

Life Science Communication Strategy of the Year

Hosted by

EQS GROUP

CRITERIA

Strength of outcome / notable achievements and future prospects

Supporting information is attributed to a 1st June 2016 - 1st June 2017 timeline.

Astex Pharmaceuticals and Instinctif (1)

Cancer and CNS disorders therapeutics

- Astex's mission is to discover and develop novel therapeutics with a primary focus in cancer and CNS disorders.
- Kisqali® (ribociclib) Receives FDA approval as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibitor.
- Novartis drug Kisqali® (ribociclib, LEE011) receives marketing approval by the US FDA as a first-line drug for HR+/HER2- advanced breast cancer in combination with an aromatase inhibitor.
- Astex's scientific expertise was instrumental in the drug's discovery by solving the crystal structure of the key cancer target CDK4.
- A strategic research collaboration with Novartis under which Astex and Novartis Institutes for BioMedical Research (NIBR) scientists jointly developed and optimised the chemical structure of Kisqali, which was then progressed through clinical trials by Novartis
- In a clinical trial, Kisqali, plus drug letrozole, has shown significant clinical benefit in all patient subgroups when compared with letrozole alone, for treatment of HR+/HER2- advanced breast cancer. From discovery to approval in 12 years.

Evgen Pharma and Buchanan (2)

Breast cancer and stroke pharmaceuticals

- Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.
- United States Patent and Trademark Office grants a patent that significantly broadens and extends the Company's intellectual property around its lead product, SFX-01.
- SFX-01 is a synthetic version of the naturally occurring compound sulforaphane, which has been stabilised in an alpha-cyclodextrin lattice. The current patent protection is composition of matter and runs until 2028. This new patent, granted today under number US9,567,405 and entitled Method of Synthesizing Sulforaphane, covers the manufacturing process and runs until 2033.
- The exclusive worldwide rights to the patent are held by Evgen Pharma under the terms of a licence agreement with PharmAgra Labs Inc., the US laboratory that invented SFX-01.
- Evgen Pharma is currently conducting two Phase II trials of SFX-01, one in advanced breast cancer and one in a type of stroke called subarachnoid haemorrhage.

F2G and Hume Brophy (3)

Antifungal pharmaceuticals

- F2G is an established UK Biotech focusing on the discovery and development of novel drugs to treat life threatening fungal diseases.
- Receives European Orphan Drug Designation for its Lead Candidate F901318 for the treatment of invasive Aspergillosis and rare mould infections caused by Scedosporium species.
- Orphan drug designation will allow F901318 up to ten years market exclusivity following market authorisation in the EU.
- F901318 is the first member of a novel class of systemic antifungal agents targeting life threatening mould infections and acting through a completely novel cellular target. F901318 is being developed for both intravenous and oral formulations and will enter Phase II clinical development in mid-2017.
- Receiving the European orphan drug designation for F901318 offers certain benefits and incentives, including marketing exclusivity, that are strategically important from a regulatory and commercial perspective. The positive decision of the EMA orphan drug committee is further validation of F901318 and our development program as we look forward to accelerating our Phase II clinical programme this year.

Heptares Therapeutics and Citigate Dewe Rogerson (4)

GPCR-targeting drug development

- Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases.
- Collaboration with AstraZeneca yields New Insights to Advance Drug Discovery in Pain, Cancer and Inflammation.
- The milestone was triggered by the successful completion of a preclinical programme that demonstrated a clear effect of AZD4635 in reversing adenosine-mediated T-cell suppression and enhancing anti-tumour immunity. Blockade of A2A signalling with AZD4635 was found to reduce tumour growth when used alone and in combination with anti-PD-L1 checkpoint inhibitors
- Achieved an important milestone in its immuno-oncology collaboration with AstraZeneca, which is focused on the development of AZD4635 (HTL-1071) as a potential new treatment for a range of cancers.
- As a result, the achievement has triggered a US$12 million payment from AstraZeneca.
- Citigate promotes Heptares' leadership position in GPCR targeted drug design and development and potential to unlock and dominate a very large market opportunity, to support fundraising and partnering activity.

Horizon Discovery and Consilium Strategic Communications (5)

DNA sequencing and personalised medicine

- Horizon Discovery is a translational genomics company developing and supplying patient-relevant drug discovery tools and diagnostic reference material.
- Announcement of new gene editing technology platform for research and therapeutics applications.
- This new gene editing technology, co-invented by Horizon's Head of Innovation Dr. Tilmann Buerckstuemmer together with three other European Scientists, has been acquired on terms that include a small upfront payment with additional downstream royalty payments to the third party co-inventors against future product sales and sub-license deals.
- Supports delivery of the DNA sequence of the protein to be manufactured into bioproduction cell lines, and holds the potential to enhance the productivity of cells by having multiple copies of the target sequence present.
- Used to efficiently develop reference standards for assays designed to measure the copy number of a gene.
- Provides an alternative mechanism to deliver a gene of interest into a genome, and opens up a potentially revolutionary approach to therapeutic development where multiple copies of an expressing gene can drive the effectiveness of therapy.

Optibiotix and Walbrook PR (6)

Biotechnological research

- OptiBiotix Health Plc is a life sciences company operating in one of the most progressive areas of biotechnological research - the modulation of the human microbiome.
- Successful Launch of LPLDL® and SlimBiome® products at Vitafoods 2017.
- OptiBiotix launched the first of its range of heart health products containing LPLDL® called CholBiome and CardioBiome, and its SlimBiome® weight management technology.
- Both product types were exhibited in the New Products Zone and at Sacco's and Nutrilinea's stands. Sacco and Nutrilinea are OptiBiotix's European manufacturing and formulation partners and have an extensive European network to maximise the commercial opportunity provided by these products.
- Both LPLDL® and SlimBiome® were extremely well received with high interest in the distribution and sale of these products from partners across Europe, Japan, India, Asia, Australia and the USA.

Verona Pharma and FTI Consulting (7)

Respiratory therapeutics

- Verona Pharma plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.
- Announcement of pricing of global offering and approval to list on the NASDAQ global market.
- £44.7m raised to fund RPL554 through a phase 2b clinical trial in chronic obstructive pulmonary disease (COPD) patients and additional phase 2 studies in both COPD and cystic fibrosis.
- Issue of 1,555,796,345 shares at a price of 2.873 pence per ordinary share.
- The funds raised from the placing will allow the company to focus on conducting a comprehensive Phase 2b clinical trial programme for nebulised RPL554 as a potential treatment for patients with COPD. We will also explore in the clinic for the first time the use of RPL554 as a novel treatment for cystic fibrosis expanding the potential of the drug into another respiratory disease where there remains a significant unmet need.

Private Life Science CEO of the Year

CRITERIA

Ability to move the business through key stages of strategic development
Securing of significant new funds for growth / strategic development
Creation of new partnerships / leveraging existing Partnerships
Strengthening of Management Team / Board
Personal Awards

Supporting information is attributed to a 1st June 2016 - 1st June 2017 timeline.

John Beadle, CEO (1)

- PsiOxus Therapeutics, an Oxford, UK-based development stage biotechnology company focused upon immune-oncology, has developed a patented platform for delivering tumor-targeted oncolytic immune therapeutics systemically.
- Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an "Armed" Oncolytic Virus to Address Solid Tumors.
- PsiOxus Therapeutics Licenses Immunotherapeutic Delivery Technology 'Polymap multivalent adjuvant technology to Avidea.
- Appointment of Dr Charles "Charlie" Morris as Chief Development Officer and Karen LaRochelle as Chief Business Officer, both of whom will be based in the United States.
- First C Level appointments in the US for the Oxford, UK based company as part of a planned expansion both in the UK and the US.

David Chiswell, CEO (2)

- Kymab receives $9m grant from the Bill & Melinda Gates Foundation to fund infectious disease research and development
- Early stage results of its new antibody treatment, KY1005, showed an improvement in post-transplant survival in an animal model of acute graft-versus-host-disease (GvHD), a common and potentially deadly complication of bone marrow transplants.
- Secured a US$100 million (£81 million) Series C financing.
- Cross-licensing and development agreement with EpimAb to develop bispecific therapeutic antibodies against multiple targets.
- Appointed Dr Sonia Quaratino as its first Chief Medical Officer. Dr Quaratino will manage the clinical development of the Group's expanding therapeutic antibody portfolio.
- Appointed Dr Arndt Schottelius as its first Executive Vice President Research & Development.

John Haurum, CEO (3)

- F-star announces an agreement with CMC Biologics for manufacture of mAb² ™ bispecific antibodies.
- F-star announces funding and collaboration extension with new Christian Doppler Lab for Innovative Immunotherapeutics.
- PUBLISHED: AUGUST 25TH, 2016F-star Announces Collaborative Agreement with Denali Therapeutics.
- Awarded "Life Science Innovation" Company of the Year by Business Weekly.
- Expands its Relationship with Merck through a new Strategic Collaboration to Develop Bispecific Antibodies in Immuno-Oncology.

Christian Itin, CEO (4)

- Signed an agreement for Autolus to become the first company to enter the CGT Catapult's manufacturing centre in Stevenage, UK. CGT Catapult is in part funded by the UK government and dedicated to supporting the growth of the UK cell and gene therapy industry by filling the gap between scientific research and commercialisation.
- New CAR-T Approach for the Treatment of T-Cell Lymphomas Presented at the December 2016 American Society of Hematology Annual Meeting.
- Data demonstrated that directing CAR-T cell therapy against a specific variant of TRBC has the potential to eliminate T cell lymphoma without eradicating the entire T cell compartment and thus preserving the patient's ability to fight viral disease.

Kevin Lee, CEO (5)

- Successful completion of a £40 million Series B financing round. Proceeds will be used to further the development of multiple drug candidates, including Bicycle's lead molecule, BT1718, a first-in-class drug for cancers of high unmet need.
- Preclinical milestone in connection with the advancement of a Bicycle into preclinical development for the treatment of diabetic macular edema, under its ophthalmology alliance with ThromboGenics.
- Named by Business Weekly as the winner of its 2017 Disruptive Technology Award.
- Announced the appointment of Nicholas Keen, Ph.D., as Chief Scientific Officer.
- Winner of the best Drug Delivery Technology category in the Fierce Innovation Awards for Life Sciences 2016.
- Collaboration with AstraZeneca for the identification and development of bicyclic peptides.

Anker Lundemose, CEO (6)

- Awarded a grant from the Michael J. Fox Foundation for Parkinson's Research (MJFF). This research grant will support the testing of Mission Therapeutics' potent and selective USP30-targeted inhibitors in translationally relevant stem cell-derived Parkinson's disease models developed by Professor Richard Wade-Martins and his research group at the University of Oxford.
- Dr Anne Phelan appointed as Senior Vice President, Head of Discovery Research.
- Dr Colin Goddard appointed as non-executive Chairman.
- Chief Medical Officer, Dr Michael Koslowski listed as one of the 20 top translational researchers of 2015 in Nature Biotechnology.
- Mission Therapeutics wins 'One to Watch' Private UK Life Science Company of the Year at Biotech and Mone Awards

Peter Pack, CEO (7)

- Crescendo Biologics nominated for Mediscience Emerging Star Award (wins 16th June)
- Appointment of Philip Bland-Ward as Chief Scientific Officer.
- Partners with software-provider, Genedata, on next-generation immuno-oncology and ADC programs.
- Appointment of Theodora Harold as Chief Financial Officer.
- Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m.
- Strengthens IP portfolio with U.S. patent to transgenic mouse platform for generating Humabody® therapeutics.

Gordon Sanghera, CEO (8)

- Raised £100 million ($126 million) in new funding through a private placement of ordinary shares. The investment round was led by new investor GT Healthcare Capital Partners ("GT Healthcare"), a pan-Asian fund with special reach in China, as well as existing investor Woodford Investment Management on behalf of its clients. Other new and existing investors including IP Group plc also participated in the round.
- Funds will oversee commercial expansion into Asia plus other territories.
- The firm is boosting production, sales and marketing for products including NimION (portable DNA sequencer, PromethION (high-throughput, on0dmeand sequencer) and VolTRAX (automated sample/library preparation decide).
- Continued investment in existing products including mobile-phone compatible SmidgION sequencer.

Public Life Science CEO of the Year

CRITERIA

Ability to move the business through key stages of strategic development
Securing of significant new funds for growth / strategic development
Creation of new partnerships / leveraging existing Partnerships
Strengthening of Management Team / Board
Personal Awards
External industry support / engagement

Supporting information is attributed to a 1st June 2016 - 1st June 2017 timeline.

John Burt, CEO (1)

- Integration of Abzena's service offering for biopharmaceutical development and manufacturing across three sites in UK and US delivering expected revenue synergies
- Licence deal with US biopharma for ThioBridge™ ADC technology for up to 10 products, with potential to deliver $300m in licence fees and milestone payments plus royalties
- Executive management team strengthened with appointment of Chief Business Officer and President, Abzena (US).
- Raised £23.9 million (net of expenses) to fund investment and growth plan to accelerate transition to profitability
- Composite Human Antibody licence deal signed with public US biotech company with potential to deliver $19 million milestone payments.

Shaun Chilton, CEO (2)

- Gross profit* expected to be up 22% driven by a combination of organic growth across all operations, a full year's contribution from Link Healthcare and currency benefits.
- Strong growth across Clinical Trial Services , Unlicensed Medicines and Commercial Medicines.
- Dexrazoxane portfolio revitalisation significantly enhanced by positive CHMP** opinion on Cardioxane and Totect US approval
- Clinigen and TESARO partner to initiate EU Managed Access Program for niraparib for patients with recurrent ovarian cancer.
- Clinigen and Cumberland Pharmaceuticals enter exclusive U.S. commercialisation agreement for Totect®.
- Clinigen and BTG extend global partnership with new exclusive Global Access agreement.
- Clinigen launches Japanese business to strengthen Asian presence.

John Dawson, CEO (3)

- Oxford BioMedica notes acceptance by FDA of a Biologics License Application (BLA) filing for CTL019.
- Major new lentiviral vector supply agreement signed with Novartis for CTL019 and other undisclosed CART products; over $100 million revenue potential over three years including $10 million upfront payment.
- Entered into a strategic alliance with Orchard Therapeutics ("Orchard"), a biotechnology company dedicated to bringing transformative ex-vivo stem cell based gene therapies to patients
- New R&D collaboration with Green Cross LabCell focused on gene modified natural killer (NK) cell-based therapies.
- £10m raised to fund progress on its discovery and pre-clinical projects.
- Establishment of a New Non-Exclusive LentiVector® Licence with MolMed.

Darrin Disley, CEO (4)

- Enters into R&D and licensing partnership with Amplycell S.A. for bioproduction cell line optimisation.
- Signs a Master Service Agreement with a Top Three Pharmaceutical Company.
- Horizon Discovery and Fulcrum Therapeutics Form Collaboration for Novel CRISPR-Based Target Discovery in Genetic Diseases.
- Horizon Discovery Group and Ventana Medical Systems Sign Co-development Agreement for Reference Standards.
- Horizon Discovery Takes Exclusive License to a Range of Melanoma Patient-Derived Xenograft Models.
- Winner of Quoted COmpany of hte Year in the Business Weekly Awards.
- Inclusion in the Maserati Top 100 list of disruptive entrepeneurs.

Clive Dix, CEO (5)

- £7m raised in 2017 to continue to build its existing pipeline of five preclinical assets.
- Strategic acquisitions made to enhance the Company's core target identification and drug design capabilities included acquiring the pioneering computational drug discovery technologies from MolPlex Ltd, further enhancing the Company's cutting-edge drug design platform.
- Completion of a £5.0 million fundraise in September 2016.
- A new multi-target risk-sharing alliance with Evotec AG ("Evotec") was announced in September 2016. Evotec and C4XD will work together on novel small molecule drugs across a range of targets, therapeutic areas and stages of development.
- Brad Hoy, CFO, and Dr Craig Fox, CSO, appointed to the BoDi in November 2016.
- Strategy to drive revenue through early-stage licensing deals around a high value, pre-clinical portfolio.

Glyn Edwards, CEO (6)

- Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit's Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy, receiving $40m upfront.
- Ezutromid, our lead utrophin modulator for DMD, achieved an important development milestone following completion of enrolment into our clinical trial called PhaseOut DMD, triggering a $22 million payment from our licence and collaboration partner Sarepta Therapeutics.
- Appointment of Dr David Roblin as Chief Operating Officer and President of Research & Development.
- Ridinilazole, our highly selective and potent antibiotic for the treatment of C. difficile infection, also continues to progress as we prepare the asset to start Phase 3 clinical trials in the first half of 2018.

Dame Louise Makin, CEO (7)

- BTG has made significant progress in executing its growth strategy and demonstrating leadership in Interventional Medicine. The business is now capable of delivering sustained double-digit product sales growth based on the momentum in Interventional Oncology and EKOS®
, together with the financial underpin from Specialty.
- Acquisition of Galil Medical, a leader in interventional oncology cryoablation technology
- Liver cancer treatment DC Bead LUMI™ , the first and only visible chemoembolising bead, approved in the EU and Canada
- Availability of TheraSphere®, the radiation treatment for liver cancer, expanded in Asia; new dosimetry software launched
- Collaboration with the Society of Interventional Oncology (SIO) to test locoregional therapies alongside immunooncology agents Vascular.

James Ward-Lilley, CEO (8)

- Oversaw Vectura buy-out of Skyepharma in a £441.3m deal.
- Company is estimated to have a market capitalisation of just over £1 billion based on each respective valuation, with joint sales of £153.9 million and profits of around £50.5 million.
- First launch of a product incorporating Vectura's FOX® smart nebuliser technology.
- Launch of Utibron™ Neohaler® in the US.
- Vectura achieves £9 million royalty cap from GSK Ellipta® products
- Seebri® / Ultibro® Breezhaler® 2016 sales reach $512 million triggering $5m milestone.
- FDA approves initial IND to support Vectura's wholly-owned programme VR647 in paediatric asthma.
- Global development programme with Mundipharma for pMDI inhaled triple therapy (VR2076) for asthma and COPD.

2017 Attending Companies

Abingworth
Abzena
Alacrita
Alzheimer's Research UK
Apcintex
Apollo Therapeutics
Arix Bioscience
Arthur J Gallagher
Artios Pharma Ltd
Astex Pharmaceuticals
AstraZeneca
Autifony
Bailey Fisher
Barclays
Bicycle Therapeutics
BioScience Managers
Biotech and Money
Bristows LLP
Brown Rudnick
Cambridge Enterprise
Cambridge Innovation Capital
Capital Cell
Carrick Therapeutics
Cenkos Securities
Chronos Therapeutics
Circadian Therapeutics
Circassia
Citigate Dewe Rogerson
Clinigen
CMS
Confluence Tax
Congenica
Consiliium Strategic Communications
Convatec
Covington & Burling
CREO Medical
Crescendo Biologics
CRT
Downing
Droia Oncology Ventures
Dyadic International
e-Therapeutics plc
Eli Lilly and Company
EQS Group
F-Star Biotechnology
F2G Ltd
Faber, Daeufer and Itrato
Finance Wales
Fladgate LLP
Forbion
Francis Crick Institute
FTI Consulting
GammaDelta Therapeutics Limited
Gilde Healthcare Partners
Haseltine Lake
Horizon Discovery
Hume Brophy
Imperial Innovations
Instinctif
iOnctura
JA Kemp
JAG Shaw Baker
Jefferies
Johnson & Johnson
King's College London
KPMG
Medicines Discovery Catapult
Medicxi
Mercia Technologies
Merck
Merck Ventures
Microbiotica
Midatech Pharma
MISSION Therapeutics
Multipharma
N+1 Singer
Nasdaq
Nightstarx Ltd
Novasecta
Oxford BioMedica (UK)
Oxford University Innovation Ltd
Oxular
Pfizer Limited
PsiOxus Therapeutics
RBC Capital Markets
ReNeuron
Scancell Ltd
SCIAD
SCIAD Communications
Shard Capital Partners
SkinBioTherapeutics
Sofinnova Partners
Spencer Stuart
Storm Therapeutics Ltd
Summit Therapeutics plc
SuperX
Syndicate Room
Taiho Ventures, LLC
Takeda Pharmaceuticals
The RSA Group
Touchstone Innovations
Tusk Therapeutics
TxCell
Verona Pharma plc
Vita Advisory
Wellington Partners
WideCells
Zeus Capital

ANNOUNCEMENT

Dear Colleague,

The World HeallthEx Forum is a powerful 2-day forum for the most innovative, influential board level industry executives involved in shaping the future of health. In 2017, the WHF takes place on Monday 13 and Tuesday 14 November.

The World HealthEx Forum is positioned as the 'Davos' of Life Sciences, bringing together industry Executives, KOLs and stakeholders in a multidisciplinary Chatham House Rule format, to engage in genuine peer-to-peer discussion, debate and bi-lateral meetings. The World HealthEx Forum emulates the outcome orientated nature of the World Economic Forum, but does so in Life Sciences.

The event combines plenary keynote sessions and bi-lateral meetings for 300 C-Level stakeholders, with 6 co-located, 40-person, CEO-level forums that focus on Immuno-Oncology, Precision Medicine, Advanced Therapies, Neuroscience & CNS, Digital Health and Medtech. The Forum also includes a 15-person Pharma BD&L Forum and an InvestEx Forum, specifically for the top 40 active VCs in Europe and UK.

Day 2 also delivers 80 showcase presentations from across the life science spectrum.

Visit www.biotechandmoney.com/world-healthex-forum for details of the current forum participants and how you could secure yourself a place alongside them.

The Biotech and Money Team

INVITATION ONLY.
CHATHAM HOUSE RULE.
EVERYONE IS AN ACTIVE PARTICIPANT, NO-ONE A DELEGATE

300+

C-SUITE EXECUTIVES FROM >$1BN PHARMA TO INDUSTRY INNOVATORS AND DISRUPTORS

8

LEADERS FORUMS WITH SUB SECTOR SPECIFIC KOLs

GENUINE ACTIONABLE OUTCOMES FOR THE SECTOR
(REPORTS, SURVEYS, FOLLOW UP EVENTS AND INITIATIVES)

DAY 1 - Monday November 13

DAY 2 - Tuesday November 14

With thanks to our Awards communication partner:

SCIAD

THE SCIENCE OF COMMUNICATIONS

SCIAD NEWSWIRE

SCIENCE AND HEALTHCARE NEWS DISTRIBUTION